Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/XILIO-THERAPEUTICS-INC-128506326/news/Xilio-Therapeutics-Inc-gibt-den-Beginn-der-Patientendosierung-in-der-klinischen-Phase-1-2-Studie-v-37608406/?utm_source=whatsapp&utm_medium=social&utm_campaign=share